ecrin-mdr-crcClinical2022IPD Sharing (as of January 2023): NoCarcinomaNon-small cell lung cancer NOSCarcinoma, Non-Small-Cell LungHepatocellular carcinoma recurrentColorectal CancerCutaneous Squamous Cell CarcinomaCarcinoma, Squamous CellOvarian CancerProstatic NeoplasmsNon-Small Cell Lung CancerOvarian cancer NOSadvanced/refractory solid tumorsColorectal NeoplasmsCarcinoma, HepatocellularOvarian NeoplasmsCastration-resistant Prostate CancerMetastatic colorectal cancerHepatocellular CarcinomaOvarian Cancer NosMetastatic Colorectal CancerCarcinomaColorectal CancerCutaneous Squamous Cell CarcinomaCarcinoma, Squamous CellOvarian CancerProstatic NeoplasmsAdvanced/refractory Solid TumorsNon-small Cell Lung CancerColorectal NeoplasmsNon-small Cell Lung Cancer NosCarcinoma, Non-small-cell LungCarcinoma, HepatocellularOvarian NeoplasmsCastration-resistant Prostate CancerHepatocellular Carcinoma RecurrentHepatocellular CarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2405953BelgiumHungaryUnited StatesCzechiaPolandUnited KingdomItalyGeorgiaFranceGermanySpain6AURELIO-04PembrolizumabMetastatic Castration-resistant Prostate CancerSOT101Advanced Hepatocellular CarcinomaKEYNOTE-D13SO-C101ECRIN MDRRecruitingfalseA Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsThe primary objective of the study is to estimate the antitumor efficacy of SOT101 in combination with pembrolizumab in selected tumors.2022-06-152405953NCT052563812021-005774-25